Notify me when BCLS Fund III Investments, LP files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| HTFL | Heartflow, Inc. | Common Stock, $0.001 par value per share | 15% | $419,004,998 | 12,448,158 | BCLS Fund III Investments, LP | 30 Sep 2025 | ||
| NAMS | NewAmsterdam Pharma Company N.V. | Ordinary Shares, nominal value Euro 0.12 per share | 4.7% | $214,462,841 | -$241,180,844 | 5,376,356 | -53% | BCLS Fund III Investments, LP | 02 Dec 2025 |
| DNTH | DIANTHUS THERAPEUTICS, INC. | Common Stock, $0.001 par value per share | 3.1% | $51,780,350 | -$45,896,187 | 1,315,892 | -47% | BCLS Fund III Investments, LP | 30 Sep 2025 |
| CDTX | CIDARA THERAPEUTICS, INC. | Common Stock, $0.0001 par value per share | 0% | $0 | -$668,786,766 | 0 | -100% | BCLS Fund III Investments, LP | 31 Dec 2025 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|